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Glioblastoma multiforme (GBM) is the most aggressive form of primary central nervous system (CNS) tumors that arise from glial 
cells. This type of cancer presents a rapid evolution and 
relapse within the first year of diagnosis even after surs
gery and radiotherapy treatments.1,2 The maximum surs
vival time after first relapse and with surgery plus temos
zolomide is about 8 months.1,2 Relapse of patients with 
GBM is attributed to the recurrence and persistence 
of tumor stem cells (TSC) which migrate to healthy 
brain tissues. Although, this population of cancer cells 
represent a small fraction of the malignant cells, they 
are exclusively responsible for propagating the disease.3 
TSCs proliferate, differentiate, and uniquely maintain 
the tumor growth while keeping their ability to selfsres
new.4 Brain TSCs are characterized by their expression 
of high levels of CD133 in addition to other normal 
neural stem cell markers such as nestin, but they lack difs
ferentiated neural lineage markers.5 TSCs were shown 
recently to resist radiation therapy and lead to tumor 
recurrence after treatment.6 Therefore, alternative thers
apies that target TSCs are crucially needed. 
GBM is characterized with a local and systemic 
immune suppression manifested with decreased cellus
lar and humoral immunity. This immune deficiency is 
believed to be due to several factors including secreted 
transforming growth factor (TGF),7 tumor cells lacks
ing the major histocompatibility complex (MHC) mols
ecules,8 cosstimulatory molecules and/or upsregulation 
of cosinhibitory molecules like B7sH1.9 In this issue 
Moviglia et al carried out a vaccine trial in a small nums
ber of patients with GBM to enhance the patients’ ims
mune response to the disease. Two vaccine preparations 
were tested: mixed leukocyte culture (MLC) and tumor 
Bscell hybridoma (TBH). MLC is a mononuclear cell 
preparation (MNC) collected from an unrelatedsuns
matched donor that is stimulated for 3 days against 
the cancer patient’s irradiatedsinactivated MNC. The 
stimulated cells are then implanted in the tumor lodge 
after neurosurgery.10 In this mode of therapy, cytokine 
production by the stimulated MNC, placed beside the 
tumor cells, might induce its regression by host antis
tumor effector mechanisms. The rationale for such 
therapy is based on previous favorable data obtained by 
the same group in patients with pancreatic cancer.10 The 
TBH vaccine was prepared from B cells obtained from 
the patients’ mononuclear cells, after in vitro culturing 
and expansion with ILs4 and ILs6, and subsequent fus
sion with TSCs obtained by mechanical dissociation of 
the tumor biopsy and culturing in vitro.11
Three different treatment combinations were given 
to 3 groups of GBM patients after first relapse of des
bulking surgery (DS) + radiotherapy (Rx): Group 1 
received DS + MLC; Group 2 received DS + MLC + 
TBH and Group 3 received DS + TBH. It was dems
onstrated that patients in Group 3 who underwent the 
TBH treatment had a longslasting median survival of 25 
months after the first immunization compared to those 
in Group 1 (MLC) who had a shorter median survival 
of 4.5 months. Group 2 (MLC + TBH) had a relatively 
higher median survival of 9.5 months. Although both 
treatments in Group 1 and 2 had a strong and rapid 
therapeutic effect compared to Group 3, treatments in 
Group 1 and 2 resulted also in brain inflammation pros
voking encephalitic autoimmune reactions which were 
absent in Group 3 treated with the TBH alone. It seems 
that the MLC reaction was the responsible for such 
brain inflammation. Another important observation in 
this study is the involvement of TSC and B cells in the 
generation of the TBH hybridoma. TCS will be an ims
portant source for provision of tumor antigens, while B 
cells expressing both stimulatory (HLA class I/II) and 
costimulatory molecules (B7.1, B7.2, CD40) and will 
act as professional antigen presenting cells. TBH may 
activate CD4+ T helper cells which in turn help in the 
generation, activation and expansion of tumor antigens
specific CD8+ cytotoxic T lymphocytes (CTL). On 
the other hand, TBH may help in the activation and 
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generation of plasma cells that can secrete antibodies 
directed against tumor surface antigens expressed by 
TSCs such as CD133. This can lead to antibody des
pendent cytotoxicity (ADCC) that can kill tumor cells 
by natural killer cells (NK). Figure 1 illustrates poss
sible humoral and cellular immune responses generated 
by TBH and their contribution to a better survival rate 
in brain cancer patients. Another practical advantage 
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REfEREnCES
of using B cells, over other antigen presenting cells, in 
the generation of the TBH hybrid, is attributed to their 
expansion and longsterm in vitro culture allowing vacs
cination of patients with the same cell preparation in sufs
ficient amounts for the whole vaccination program.
It seems that the immune response generated against 
TSC antigens will prevent tumor escape of immune surs
veillance by eliminating tumor recurrence after relapse. 
Figure	1.	possible 
humoral and 
cellular immune 
responses 
generated by 
TBH and their 
contribution to a 
better survival rate 
in brain cancer 
patients. 
aDCC= antibody dependent cytotoxicity, CTl= Cytotoxic T lymphocytes, TBH= Tumor Bbcell hybrid, nK= natural killer cells
